Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia
Badalona, Barcelona, Spain
General hospital in Spain
Carretera de Canyet, s/n, 08916 Badalona, Barcelona
About Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
10
Clinical Trials at Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia
During the past decade, Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 5 clinical trials were completed, i.e. on
average, 83.3% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 1 clinical trials were completed. i.e. 25%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
2011-07-06
2021-07-30
Completed
1,401
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
2011-12-20
2018-06-02
Completed
692
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
2013-11-04
2018-10-08
Completed
979
A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia
2014-04-09
2018-11-19
Completed
72
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
2017-02-21
2025-08-28
Active, not recruiting
860
A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma
2017-11-13
2021-05-18
Completed
49
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2020-02-07
2025-12-31
Recruiting
260
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
2020-05-28
2025-06-28
Active, not recruiting
165
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia"
#1 collaborator was "Chugai Pharmaceutical" with 2 trials as a collaborator, "German Low Grade Lymphoma Study Group" with 1 trials as a collaborator and "Institute of Cancer Research, United Kingdom" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were
collaborators in the rest 3 trials.
Clinical Trials Conditions at Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia
According to Clinical.Site data, the most researched conditions in "Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia" are
"Non-Hodgkin's Lymphoma" (3 trials), "Chronic Lymphocytic Leukemia" (2 trials), "Paroxysmal Nocturnal Hemoglobinuria" (2 trials), "Chronic Lymphocytic Leukemia (CLL)" (1 trials) and "Diffuse Large B-Cell Lymphoma" (1 trials). Many other conditions were trialed in "Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia" in a lesser frequency.
Clinical Trials Intervention Types at Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia
Most popular intervention types in "Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia" are "Drug" (10 trials). Other intervention types were less common.
The name of intervention was led by "Obinutuzumab" (4 trials), "Rituximab" (4 trials), "Bendamustine" (3 trials), "Cyclophosphamide" (3 trials) and "Crovalimab" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia
The vast majority of trials in "Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia" are
10 trials for "All" genders.
Clinical Trials Status at Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia
Currently, there are NaN active trials in "Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia".
undefined are not yet recruiting,
2 are recruiting,
3 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 5 completed trials in Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia, 2 "Phase 1"
clinical trials were conducted, 3 "Phase 2" clinical
trials and 7 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".